Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23853488 | 1.00 | GAA (1.00) | GAAAHRHSD17B10EPAS1PTGS1 | |
| SCHEMBL29438413 | 0.84 | HSD17B10 (0.73) | GAAAHRHSD17B10PTGS1P2RX1 | |
| SCHEMBL29438464 | 0.83 | GAA (0.71) | GAAAHRHSD17B10LCKKDR | |
| SCHEMBL29438428 | 0.82 | GAA (0.69) | GAAAHRHSD17B10EPAS1MAPT | |
| SCHEMBL3421414 | 0.80 | HSD17B10 (0.65) | GAAAHRHSD17B10MAPTMEN1 | |
| SCHEMBL29059356 | 0.79 | EPAS1 (0.79) | GAAAHRHSD17B10EPAS1PTGS1 | |
| SCHEMBL29059173 | 0.78 | EPAS1 (1.00) | GAAAHRHSD17B10EPAS1PTGS1 | |
| SCHEMBL29438441 | 0.78 | GAA (0.64) | GAAAHRHSD17B10EPAS1MAPT | |
| SCHEMBL31424184 | 0.78 | PTGS1 (1.00) | GAAAHRHSD17B10PTGS1RXFP1 | |
| SCHEMBL4031509 | 0.78 | PTGS1 (1.00) | GAAAHRHSD17B10PTGS1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064167-A1 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | AVIDIN KFT. (HU) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064167-A1 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | MYD88, MCL1, MYADM | GAA 4744/4885AHR 881/4885HSD17B10 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.